Angioedema Treatment Market Revenue and Value Chain 2016-2026
Allergies affect about 30% of the adults and 40% of children and are increasing day by day. It is the fifth leading cause of chronic diseases affecting approximately 50 million people in the United States. Angioedema is one of the common condition caused due to allergies and show sudden swelling under the skin surface. It is also sad to be the most dangerous form of hives and can affect hands, feet, lips, eye lids and genitals. There are four different types of angioedema as allergic angioedema, idiopathic angioedema, drug-induced angioedema and hereditary angioedema. The treatment of angioedema may include a normal physical examination, even though with proper medication angioedema cannot be completely cured but regular drugs can help in preventing the attacks in the patients. Allergic angioedema and idiopathic angioedema can be treated using combination drugs and helped relieving swelling. In case of severe cases of angioedema steroid injections may be needed.
In the United States it was reported that in 2010 the total spending on allergies was $17.5 billion from which food allergies cost about $25 million, thus people having severe allergies and changing life-style can be the major factors contributing the growth of the angioedema treatment market. The increasing rate of angioedema in the United States and other regions has triggered the demand for hospitalization and advancements in the treatment of angioedema. Though angioedema can be treated, it cannot be completely cured and rapidly increasing allergic conditions can give rise to epidemiology, such factors are responsible for hindering the growth of the market. The crucial challenge for the pharmaceuticals is enhance and advance the treatment for angioedema and come up with better drugs.
Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1712
The global market for Angioedema Treatmentis segmented on basis of treatment and end use:
Segmentation by treatment for Angioedema Treatment
- Drugs Class
- Antigonadotropic agents
Segmentation by end use for Angioedema Treatment
- Research Organizations
Globally the number of allergies and allergy conditions as angioedema are rapidly increasing, thus the angioedema treatment market is estimated to have an enormous growth during the forecast period (2016-2026). Pharmaceuticals and research organizations are working to develop novel drug and treatments for angioedema. Improving medical facilities and health insurances along with advance technology the market for angioedema treatment will boost in coming years.
Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1712
On the basis of region presence, Angioedema Treatment market is segmented into five key regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
Currently, North America dominates the global market for Angioedema Treatment due to high prevalence rate of sinusitis, followed by Europe. According to the epidemiology took place in America in 2010 had increased the hospitalization rate and increasing allergies in adults and children have triggered the growth rate of angioedema. However factors such as climatic conditions inappropriate for angioedema patients and lack of awareness among people about angioedema will hamper the market growth in regions like Asia-pacific and RoW.
Some of the key market players in the manufacturing of the treatment products (drugs) for angioedema treatment includes AstraZeneca plc, F. Hoffmann-La Roche AG, Valeant Pharmaceuticals International, GlaxoSmithKline plc, AstraZeneca Plc, Sanofi S.A and Merck & Co., Inc.